Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7645
Reference
Drug alert 27/2022
Name
Drug alert class 4 - 27 2022 - class 4 medicines defect information - caution in use: [Napp Pharmaceuticals Ltd] - OxyContin 20 mg prolonged release tablets
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
Description
Napp Pharmaceuticals Limited have identified an error relating to the Braille printed on the cartons. The Braille message on the Oxycontin 20mg prolonged release tablets incorrectly states strength as 15mg.
Contact Name
Contact Email
Contact Address
Scottish Government<br> St Andrew’s House<br> Regent Road<br> Edinburgh EH1 3DG.
Contact Phone
Created
2022-06-04 00:00:00
Click to go back to homepage